Working… Menu
Trial record 3 of 5 for:    FLAURA

First Line Osimertinib for EGFR Mutation-positive Non-Small Cell Lung Cancer in Real World Chinese Setting

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04391283
Recruitment Status : Recruiting
First Posted : May 18, 2020
Last Update Posted : January 12, 2021
Information provided by (Responsible Party):
First Affiliated Hospital of Zhejiang University

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 2022
Estimated Study Completion Date : December 2022
Publications of Results:
Other Publications: